Skip to main content
. 2021 May 21;44(7):1604–1612. doi: 10.2337/dc21-0318

Figure 3.

Figure 3

Pharmacological outcomes. Median changes from baseline of GADA and proliferation (Pr) of PMBC (stimulation index [SI]) (A) and GAD-stimulated secretion by PBMC of IL-10 and IL-13 levels (B) for GAD-alum–treated patients with and without the DR3-DQ2 haplotype as well as placebo-treated patients. P values by Wilcoxon test are indicated.